摘要:

We studied the anti-HCV prevalence in the same period in all the dialysis patients, staff members and blood donors of the same geographical area. In our opinion, the low prevalence (10.26%) in dialysis patients is strictly correlated to the low prevalence (0.46%) in blood donors.

ISSN:1660-8151    

DOI:10.1159/000186936

出版商:S. Karger AG    

年代:1992

数据来源: Karger

摘要:

Sera from 209 dialysis patients were tested for antibodies to hepatitis C virus (anti-HCV) by a 2nd generation enzyme-linked immunoassay (ELISA 2) using nonstructural and core antigens. Confirmation of reactivity was obtained by a 2nd generation immunoblot assay (RIBA 2) for antibodies to 4 separate antigens (5-1-1, c100-3, c33c, c22-3). ELISA 2 was positive in 99 sera, 95 of which were confirmed by RIBA 2, thus accounting for an anti-HCV prevalence of 45.5%. Anti-HCV positivity was correlated to longer duration of dialysis therapy (p < 0.001), higher number of transfusions (p < 0.001), history of kidney transplant (p < 0.001) and of serum alanine/aspartate aminotransferase (AST/ALT; p < 0.001) or γ-glutamyltransferase (GGT) (p < 0.001) increments. The most frequent RIBA 2 patterns were: reactivity to all 4 antigens (34 patients) and to c33c and c22-3 (45 patients). The former patients, compared to the latter, had higher values of AST (p < 0.08), ALT (p < 0.02), GGT (p < 0.005), IgG (p < 0.05). It is possible that the reactivity to all 4 antigens of RIBA 2 is a clue of a greater activity of viral hepatic disease

ISSN:1660-8151    

DOI:10.1159/000186937

出版商:S. Karger AG    

年代:1992

数据来源: Karger

摘要:

We studied the prevalence and significance of antibodies to hepatitis C virus (HCV) in patients and staff from 3 dialysis units, using a 2nd generation assay (2nd g.a.; Ortho HCV). Of 277 patients, 151 (55%) were positive by 2nd and 85 (31%) by 1st g.a. Significant associations with the anti-HCV carrier status were: blood transfusions, retrospective finding of elevated ALT and duration of dialysis treatment, independently of transfusions. Of the 74 staff members, 5 were positive by 2nd and 3 by 1st g.a. Our data suggest that the 2nd g.a. is more sensitive in detecting HCV exposure in dialysis units and that duration of dialysis is a significant factor in acquiring HCV infection.

ISSN:1660-8151    

DOI:10.1159/000186938

出版商:S. Karger AG    

年代:1992

数据来源: Karger

摘要:

The immunogenicity of a recombinant hepatitis B vaccine was evaluated in 35 hemodialysis patients who received a standard dose (20 μg) of the vaccine at 0,1, 2 and 6 months. After the full vaccination course (month 7), 60% (21/35) of the patients had seroconverted (anti-HBs titer ≥10 mlU/ml). The duration of protection lasted up to 18 months after the start of vaccination in 85.7% (18/21) of the responders. At that time, an additional dose was given to all the patients: 1-2 months later, the overall immunization rate had increased to 65.7% (23/35); lastly, in month 24 (i.e., 6 months after the booster dose), 62.5% (15/24) of the patients available for evaluation were still maintaining protective levels of anti-HBs antibodies. Comparable results had previously been obtained in 21 well-matched patients on our dialysis program who were vaccinated with a plasma-derived vaccine according to the recommended schedu

ISSN:1660-8151    

DOI:10.1159/000186939

出版商:S. Karger AG    

年代:1992

数据来源: Karger

摘要:

Research was carried out on 74 hemodialysis patients to determine the frequency of anti-HCV antibodies; this was done by means of the 1st and 2nd generation screening and control tests. The 1st generation tests showed 9 HCV-seropositive patients, while the 2nd generation tests demonstrated 15 HCV-seropositive patients. It seems evident that the 2nd generation tests are more sensitive than those of the 1st.

ISSN:1660-8151    

DOI:10.1159/000186940

出版商:S. Karger AG    

年代:1992

数据来源: Karger

摘要:

The authors report on the presence of anti-HCV antibodies in a uremic chronic (UC) patient population after 6 months and 1 year with regard to certain selective preventive measures. The nonincreased number of HCV-positive subjects among the UC population could lead to the conclusion that the risk of environmental spreading of HCV is less than the risk of HBV diffusion.

ISSN:1660-8151    

DOI:10.1159/000186941

出版商:S. Karger AG    

年代:1992

数据来源: Karger

摘要:

Thymopentine is a synthetic immunomodulator that positively affects T-lymphocyte maturation, reproduction and differentiation. In elderly uremic patients nonresponders to hepatitis B vaccine, the administration of this drug has been shown to improve the response to the new vaccination.

ISSN:1660-8151    

DOI:10.1159/000186942

出版商:S. Karger AG    

年代:1992

数据来源: Karger

摘要:

The authors evaluated the response rate to HBV vaccination in 27 dialyzed patients. In the 1st stage, the response was 70.37%; nonresponder patients (n = 8) were treated with thymostimulin and revaccinated. The total percentage increased to 85.18%. In order to restore a normal response, the authors suggest to treat nonresponder patients with thymostimulin before revaccination.

ISSN:1660-8151    

DOI:10.1159/000186943

出版商:S. Karger AG    

年代:1992

数据来源: Karger

摘要:

Since HCV appears to be the major cause of post-transfusion non-A, non-B hepatitis in Italy, this study determines the presence of anti-HCV in a risk group. Among 26 patients, 9 were anti-HCV in a risk group. Among 26 patients, 9 were anti-HCV positive with the ELISA test and all of them were confirmed with the RIBA test of 2nd generation. Only 1 had a poussés movement of ALT levels. Hemodialyzed patients are reactive for HCV probably for the transfusional therapy

ISSN:1660-8151    

DOI:10.1159/000186944

出版商:S. Karger AG    

年代:1992

数据来源: Karger

摘要:

The present study refers to the evaluation of the prevalence of anti-HCV positivity and its correlation with biochemical markers of chronic liver disease (negative), dialytic age (positive) and blood transfusions (negative) in 56 hemodialized patients.

ISSN:1660-8151    

DOI:10.1159/000186945

出版商:S. Karger AG    

年代:1992

数据来源: Karger